Peptides DB
Research-centric peptide and protocol reference hub

Survodutide (BI 456906) record · updated 6h ago

Metabolic & appetiteGrade A · human clinicalResearch use only
All 5 studiesJump to the evidenceCompare
What is Survodutide (BI 456906) used for?

Dual GLP-1/Glucagon Receptor Agonist | Weight Loss & Diabetes

Primarily researched for · Metabolic & appetite

Development stage

where Survodutide (BI 456906) sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Current
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 18 registered trials. It describes the research record, not a recommendation.

Identity
NameSurvodutide (BI 456906)
Full name—
Sequence—
ClassMetabolic
Research levelWell Studied
Discovered byCurated master list · 2026
Pharmacology
Mechanism—
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence—
Effect profile · 0–5
Metabolic & appetite: Healing 0.0, Muscle 0.0, Metabolic 5.0, Neuro 0.0, Sleep 0.0, Immune 0.0, Skin 0.0Metabolic & appetite — 5.0 / 5HealingMuscleMetabolicNeuroSleepImmuneSkin0.00.05.00.00.00.00.0
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o mini over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Jul 27, 2026. How this works →
Research stats
Total studies5
Human / animal / cellular3 / 1 / 0
Highest trial phasePhase 2
Years covered2023–2025
Latest study11d ago
Publication history
20232025
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

5 rowsOpen in the library →
StudyTypeYearSummary depth
Therapeutic horizons in metabolic dysfunction-associated steatohepatitis.
Finding–30.1% relative reduction in liver fat content at 24 weeks, n=150, p<0.001
—2023Partial text0.50
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.
Finding-14.9% bodyweight change at 4.8 mg, 95% CI -16.9 to -13.0
Human2024Full text read0.80
The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.
FindingAUC improvement of 54% for survodutide vs. vehicle.
Animal2024Full text read0.70
Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial.
FindingNot reported in abstract.
Human2024Full text read0.70
An experimental medicine protocol for exploring the haemodynamic effects of dual agonism at the glucagon-like peptide-1 and glucagon receptor in healthy subjects.
FindingCo-infusion increased rate pressure product by 793 mmHg*bpm (95% CI 460-1127 mmHg*bpm, P < .001).
Human2025Full text read0.80